Previous 10 | Next 10 |
Program aims to be first disease-modifying treatment for this serious neurogenetic disorder Ultragenyx receives an exclusive option to acquire GeneTx NOVATO, Calif. and DOWNERS GROVE, Ill., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmac...
NOVATO, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg, the company’s Chief Business ...
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2019 Earnings Conference Call August 01, 2019 05:00 PM ET Company Participants Danielle Keatley - Senior Director of Investor Relations & Corporate Communication Emil Kakkis - Chief Executive Officer & President Shalini Sharp - Chi...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q2 GAAP EPS of -$1.72 misses by $0.02 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Strong Crysvita® (burosumab) Launch Continues with Approximately 960 Patients on Reimbursed Commercial Therapy in the United States Ultragenyx Submits New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders NOVATO, Calif....
NOVATO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that it has submitted to the U.S. Food and Drug Administration ...
ACA , ACOR , AIV , ALEX , ANET , APHA , BFAM , BGS , BIO , BL , BLDR , BMRN , BRKR , BRKS , BZH , CATM , CBLK , CC , CENT , CENX , CERS , CORT , CRC , CWK , CWST , DLB , DVA , EBS , ECOL , ED , ENSG , EOG , ERII , ETSY , FBHS , FLDM , FLR , FND , FRT , ...
NOVATO, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, August...
Shares of Ultragenyx Pharmaceutical ( RARE ) have risen by 37% since my January update recommended readers establish a pilot position and accumulate dips in the near term as a turnaround appeared likely. Now that the stock has pulled back from highs last seen in April, I'm looking forward ...
Mirth is like a flash of lightning that breaks through a gloom of clouds and glitters for a moment. ” ― Joseph Addison Today, we look at a small RNA developmental concern whose stock has had a nice run over the past few weeks. Can the rally continue? We take an in-depth inve...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...